现代联合模式治疗年轻霍奇金淋巴瘤患者的复发风险与预期寿命损失:北欧淋巴瘤流行病学研究组研究
基于北欧2582例18至49岁经典型霍奇金淋巴瘤患者(2000–2013年诊断)的队列,5年总生存率为95%,5年复发风险总体为13.4%,达到EFS24后降至4.2%;达到EFS24后5年内预期寿命损失仅13天,支持有限度的以复发为导向的临床随访。
要点
- 5年总生存率95%(95%CI 94%–96%),5年复发风险总体13.4%(95%CI 12.1%–14.8%)。
- 达到EFS24者5年复发风险降至4.2%(95%CI 3.8%–4.6%)。
- 达到EFS24后5年内预期寿命损失仅13天(95%CI 7–20天),支持有限度复发导向随访。
核心结论
- 北欧真实世界数据显示年轻经典型霍奇金淋巴瘤患者结局优秀,达到EFS24者预后尤其有利,支持有限度的以复发为导向的临床随访。
研究设计与样本
- 基于北欧队列的观察性研究,纳入2000年至2013年间诊断、年龄18至49岁的经典型霍奇金淋巴瘤患者2582例。
- 估算所有患者及达到12、24、36或60个月无事件生存(EFS12、EFS24、EFS36、EFS60)患者的5年复发风险和5年限制性预期寿命损失。
- 中位随访时间9年(范围2.9至16.8年)。
主要发现
- 5年总生存率为95%(95%CI 94%至96%)。
- 5年复发风险总体为13.4%(95%CI 12.1%至14.8%),达到EFS24后降至4.2%(95%CI 3.8%至4.6%)。
- 接受6至8个疗程BEACOPP方案(博来霉素、依托泊苷、多柔比星、环磷酰胺、长春新碱、丙卡巴肼、泼尼松)患者的复发风险与接受6至8个疗程ABVD方案(多柔比星、博来霉素、长春碱、达卡巴嗪)患者相当,尽管BEACOPP组不良风险标准更多。
- 从诊断时起及达到EFS24后,随后5年内预期寿命损失均较小:从诊断时起为45天(95%CI 35至54天),达到EFS24者为13天(95%CI 7至20天)。
- 在5年限制性预期寿命损失的分期分层分析中,I至IIA期患者达到EFS24后无值得注意的额外死亡风险,而IIB至IV期患者的风险仍可测量。
关键数值与推荐
- 5年总生存率95%(95%CI 94%至96%)。
- 5年复发风险总体13.4%(95%CI 12.1%至14.8%),达到EFS24后4.2%(95%CI 3.8%至4.6%)。
- 从诊断时起5年内预期寿命损失45天(95%CI 35至54天),达到EFS24后13天(95%CI 7至20天)。
临床怎么用
- 作者认为达到EFS24后预后尤其有利,支持有限度的以复发为导向的临床随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Estimates of short- and long-term survival for young patients with classic Hodgkin lymphoma (cHL) are of considerable interest. We investigated cHL prognosis in the era of contemporary treatment at different milestones during the follow-up. PATIENTS AND METHODS: On the basis of a Nordic cohort of 2,582 patients diagnosed at ages 18 to 49 years between 2000 and 2013, 5-year relapse risks and 5-year restricted losses in expectation of lifetime were estimated for all patients and for patients who achieved event-free survival (EFS) for 12 (EFS12), 24 (EFS24), 36 (EFS36) or 60 (EFS60) months. The median follow-up time was 9 years (range, 2.9 to 16.8 years). RESULTS: The 5-year overall survival was 95% (95% CI, 94% to 96%). The 5-year risk of relapse was 13.4% (95% CI, 12.1% to 14.8%) overall but decreased to 4.2% (95% CI, 3.8% to 4.6%) given that patients reached EFS24. Relapse risk for patients treated with six to eight courses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) was comparable to that of patients treated with six to eight courses of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) despite more adverse risk criteria among patients treated with BEACOPP. Both from diagnosis and if EFS24 was reached, the losses in expectation of lifetime during the following 5 years were small (from diagnosis, 45 days [95% CI, 35 to 54 days] and for patients who reached EFS24, 13 days [95% CI, 7 to 20 days]). In stage-stratified analyses of 5-year restricted loss in expectation of lifetime, patients with stages I to IIA disease had no noteworthy excess risk of death after they reached EFS24, whereas risk remained measurable for patients with stages IIB to IV cHL. CONCLUSION: Real-world data on young patients with cHL from the Nordic countries show excellent outcomes. The outlook is particularly favorable for patients who reach EFS24, which supports limited relapse-oriented clinical follow-up.
引用
- Biccler JL, Glimelius I, Eloranta S, et al. Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. J Clin Oncol. 2019. PMID: 30726176. doi:10.1200/JCO.18.01652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。